Shots:

• Boehringer Ingelheim (BI) and Amal Therapeutics enter into a clinical research agreement to conduct P-Ib KISIMA-01 study assessing Amal’s ATP128 and BI’s BI754091 with microsatellite stable (MSS) patients with stage IV colorectal cancer
• Amal to sponsor the P-Ib KISIMA-01 and will retain development & commercialization rights for ATP128 and the KISIMA technology. BI to provide its BI754091 for the trial with results jointly owned by the companies and study is expected to initiate in H2’19
• Amal’s ATP128 is a chimeric recombinant protein based on KISIMA technology targeting colorectal cancer. BI’s BI754091 is an anti PD-1 mAb- currently evaluated for solid tumors- head and neck cancer- NSCLC

Ref: Amal Therapeutics | Image: News Times